LBPSW
4D pharma plc [LBPSW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LBPSW Stock Summary
In the News
LBPSW Financial details
Company Rating
-
Market Cap
0
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
127
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
0.81
LT Debt / Equity
0.39
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-17.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0442-0.0442
52W High
-
52W Low
-
RSI
52.68
Rel Volume
-
Avg Volume
-
Volume
Perf Week
16.67%
Perf Month
133.33%
Perf Quarter
-
Perf Half Y
133.33%
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0035
Change
0%
LBPSW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.03 | 0.04 | 0.03 | |
| Net income per share | -2.51 | -2.89 | -2.94 | -1.82 | -1.51 | |
| Operating cash flow per share | -2.11 | -2.8 | -2.63 | -1.59 | -1.79 | |
| Free cash flow per share | -2.37 | -2.87 | -2.71 | -1.61 | -1.8 | |
| Cash per share | 6.15 | 3.2 | 0.47 | 0.62 | 0.99 | |
| Book value per share | 8.58 | 5.59 | 2.73 | 1.97 | 1.53 | |
| Tangible book value per share | 6.77 | 3.83 | 1.02 | 0.98 | 0.63 | |
| Share holders equity per share | 8.58 | 5.59 | 2.73 | 1.97 | 1.53 | |
| Interest debt per share | 0.02 | 0.05 | 0.2 | 0.09 | 0.63 | |
| Market cap | 87.59M | 93.54M | 90.18M | 151.91M | 85.56M | |
| Enterprise value | 75.76M | 77.51M | 87.46M | 144.2M | 77.39M | |
| P/E ratio | -4.28 | -3.95 | -3.75 | -5.85 | -2.68 | |
| Price to sales ratio | 0 | 0 | 427.4 | 284.48 | 119.16 | |
| POCF ratio | -5.1 | -4.08 | -4.18 | -6.7 | -2.26 | |
| PFCF ratio | -4.55 | -3.98 | -4.07 | -6.65 | -2.24 | |
| P/B Ratio | 1.26 | 2.04 | 4.04 | 5.43 | 2.64 | |
| PTB ratio | 1.26 | 2.04 | 4.04 | 5.43 | 2.64 | |
| EV to sales | 0 | 0 | 414.49 | 270.03 | 107.78 | |
| Enterprise value over EBITDA | -3.31 | -2.88 | -3.17 | -4.98 | -2.58 | |
| EV to operating cash flow | -4.41 | -3.38 | -4.06 | -6.36 | -2.04 | |
| EV to free cash flow | -3.93 | -3.3 | -3.95 | -6.31 | -2.03 | |
| Earnings yield | -0.23 | -0.25 | -0.27 | -0.17 | -0.37 | |
| Free cash flow yield | -0.22 | -0.25 | -0.25 | -0.15 | -0.45 | |
| Debt to equity | 0.11 | 0.15 | 0.37 | 0.27 | 0.81 | |
| Debt to assets | 0.1 | 0.13 | 0.27 | 0.21 | 0.45 | |
| Net debt to EBITDA | 0.52 | 0.6 | 0.1 | 0.27 | 0.27 | |
| Current ratio | 11.6 | 6.4 | 1.8 | 2.59 | 5.21 | |
| Interest coverage | -267.48 | -103.45 | -80.69 | -237.73 | -64.13 | |
| Income quality | 0.84 | 0.97 | 0.9 | 0.87 | 1.19 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 7.45 | 7.67 | 22.13 | |
| Research and developement to revenue | 0 | 0 | 125.65 | 41.28 | 30.13 | |
| Intangibles to total assets | 0.19 | 0.27 | 0.46 | 0.4 | 0.33 | |
| Capex to operating cash flow | 0.12 | 0.02 | 0.03 | 0.01 | 0.01 | |
| Capex to revenue | 0 | 0 | -2.82 | -0.33 | -0.39 | |
| Capex to depreciation | -2.12 | -0.45 | -0.46 | -0.15 | -0.21 | |
| Stock based compensation to revenue | 0 | 0 | 1.27 | 6.24 | 0.99 | |
| Graham number | 22.02 | 19.08 | 13.44 | 8.98 | 7.2 | |
| ROIC | -0.54 | -1.62 | -1.56 | -2.41 | -2.45 | |
| Return on tangible assets | -0.32 | -0.62 | -1.45 | -1.21 | -0.81 | |
| Graham Net | 5.18 | 2.39 | -0.53 | 0.1 | -0.25 | |
| Working capital | 52.82M | 27.98M | 5.01M | 10.27M | 27.88M | |
| Tangible asset value | 55.11M | 31.32M | 8.36M | 13.95M | 13.27M | |
| Net current asset value | 49.85M | 26.32M | 3.01M | 9.27M | 8.12M | |
| Invested capital | 0 | 0 | 0.05 | 0.04 | 0.39 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.48M | 1.87M | 1.58M | 2.26M | 2.49M | |
| Average inventory | 245.5K | 271.5K | 244K | 244.5K | 329.05K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.29 | -0.52 | -1.08 | -0.93 | -0.99 | |
| Capex per share | -0.26 | -0.07 | -0.07 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2021-12-31 for Q4
| Metric | History | 2019-06-30 | 2020-06-30 | 2020-12-31 | 2021-06-30 | 2021-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0 | 0 | 0 | |
| Net income per share | 0 | -0.3 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0.43 | 0 | 0 | 0 | |
| Book value per share | 0 | 1.35 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 1.35 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 1.35 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0.05 | 0 | 0 | 0 | |
| Market cap | 0 | 270.98M | 0 | 0 | 0 | |
| Enterprise value | -11.8M | 262.05M | -7.72M | -19.74M | -8.17M | |
| P/E ratio | 0 | -9.87 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 1.97K | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 8.61 | 0 | 0 | 0 | |
| PTB ratio | 0 | 8.61 | 0 | 0 | 0 | |
| EV to sales | 0 | 1.91K | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | -34.57 | 0 | 0 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0 | -0.03 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.22 | 0.27 | 0.27 | 0.2 | 0.81 | |
| Debt to assets | 0.18 | 0.21 | 0.21 | 0.17 | 0.45 | |
| Net debt to EBITDA | 0 | 1.18 | 0 | 0 | 0 | |
| Current ratio | 6.62 | 3.16 | 2.59 | 4.22 | 5.21 | |
| Interest coverage | 0 | 187.8 | 0 | 0 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 16.01 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 45.16 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0.4 | 0 | 0.33 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | -0.58 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -0.26 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 3 | 0 | 0 | 0 | |
| ROIC | 0 | -0.54 | 0 | 0 | 0 | |
| Return on tangible assets | 0 | -0.17 | 0 | 0 | 0 | |
| Graham Net | 0 | 0.07 | 0 | 0 | 0 | |
| Working capital | 18.99M | 14.02M | 10.27M | 22.67M | 27.88M | |
| Tangible asset value | 34.97M | 31.46M | 13.95M | 39.66M | 13.27M | |
| Net current asset value | 14.78M | 12.02M | 9.27M | 21.72M | 8.12M | |
| Invested capital | 0.03 | 0.03 | 0.04 | 0.03 | 0.39 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 4.86M | 5.13M | 4.32M | |
| Average inventory | 0 | 0 | 251.5K | 298K | 152.5K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | -0.22 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
LBPSW Frequently Asked Questions
What is 4D pharma plc stock symbol ?
4D pharma plc is a GB stock and trading under the symbol LBPSW
What is 4D pharma plc stock quote today ?
4D pharma plc stock price is $0.0035 today.
Is 4D pharma plc stock public?
Yes, 4D pharma plc is a publicly traded company.
Company Profile
- Employee 127
- CEO Mr. Duncan Joseph Peyton
- Headquarters Leeds,GB
- IPO Date 2021-03-23
-
Website
http://www.4dpharmaplc.com 
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease. It also develops immuno-oncology products comprising MRx0518, MRx0573, and MRx1299 for solid tumors, and MRx0518 for pancreatic cancer; respiratory products, such as MRx-4DP0004 for asthma and COVID-19; central nervous system products, including MRx0005 and MRx0029 for neurodegeneration; and platform products comprising vaccines and autoimmune. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.
